Laryngeal Cancer

Knowledge Check

Exam-style MCQs aligned with these notes. Available to Hyperexcision Scholar members.

Log in to access
Last updated: May 7, 2026Bookmark

Laryngeal cancer is the second most common head and neck cancer. The most common type is squamous cell carcinoma (SCC)

It peaks between 40 and 70 years of age. The 5-year survival rate is 65%.

Regions of the larynx

SiteAnatomical boundariesHistology
Supraglottic SiteFrom the epiglottis to the junction of the ventricle and the true vocal cordRespiratory epithelium
Glottic SiteFrom the superior surface of the true vocal fold to 1 cm below the true vocal foldsStratified squamous epithelium
Subglottic SiteFrom 1cm below the true vocal folds to the inferior cricoid cartilageRespiratory epithelium

Histological subtypes of laryngeal cancer

HistologyDescription
Squamous Cell Carcinoma>95% of Laryngeal Cancer. Basaloid SCC is the most aggressive high-grade variant.
Verrucous Carcinoma (Ackerman’s Tumor)Slow-growing and locally destructive. Appears exophytic (warty), fungating, and grey-white in color. It rarely metastasizes and has an excellent prognosis.
Adenocarcinoma1% of laryngeal cancer. Primarily in the supraglottic and subglottic regions. More aggressive than SCC.
Adenoid Cystic CarcinomaPerineural spread, an indolent course, and may present with distant metastasis years after primary treatment
Spindle Cell CarcinomaPoorly differentiated variant of SCC with spindle cell stroma component
Neuroendocrine TumorsParagangliomas, Carcinoid tumors, Small cell carcinoma
SarcomasFibrosarcoma, chondrosarcoma, malignant fibrous histiocytoma, rhabdomyosarcoma
MetastaticRare. Primaries from the kidney, prostate, breast, stomach, and lung.

Premalignant glottic lesions

HistologyDescription
Hyperplasia and HyperkeratosisAn increase in the number of cells and keratin production
Mild DysplasiaMild atypia
Moderate DysplasiaModerate atypia
Severe Dysplasia (Carcinoma in Situ)Full-thickness features of malignancy without invasion of the basement membrane
Microinvasive CarcinomaDiscrete foci invade beyond the basement membrane
Invasive CarcinomaInvasion through the basement membrane

Subsites of laryngeal cancer

FeatureSupraglotticGlotticSubglottic
Frequency~40%~60% (most common)Rare
PrognosisPoor (early spread, late detection)Best (early symptoms)Poor
Lymphatic SpreadRich → early, bilateral nodal spread (II–IV)Poor → late, ipsilateral spreadTo paratracheal nodes (Level VI)
Tumor Spread PatternSuperior → base of tongueLimited initially (ligament barriers)Inferior → cricoid, trachea
Special FeatureThe fusion plate limits the spread between regionsBarriers (vocal ligament, conus elasticus)Silent progression
Key Early SymptomSore throat, dysphagiaHoarsenessStridor
Other SymptomsHemoptysis, aspiration, odynophagia, otalgia, weight lossStridor (late), dysphagia, weight lossLate hoarseness, hemoptysis, dysphagia
Unique EntityMarginal tumor (aggressive, basaloid SCC)
  • Risk factors
    • Smoking and alcohol use
      • The highest risk is in current smokers
      • Risk increases with the number of cigarettes
      • Risk reduces to the level of an individual who has never smoked approximately 20 years after cessation
    • History of Recurrent Respiratory Papillomatosis (HPV)
    • Previous head and neck Radiation
    • Plummer-Vinson Syndrome
    • Premalignant lesions
      • Leukoplakia
      • Hyperkeratosis with atypia
      • Carcinoma in Situ
    • Genetic mutations in p53, p16, and cyclin D1
    • Occupational toxins
      • Asbestos
      • Wood dust
      • Coal dust
      • Cement dust
      • Polycyclic aromatic hydrocarbons
    • Fanconi’s anemia
    • Congenital dyskeratosis
    • Low socioeconomic status
  • Signs and symptoms
    • Hoarseness
      • Persistent
    • Stridor (Airway obstruction)
    • Dysphagia
    • Odynophagia
    • Throat pain
    • Haemoptysis
    • Referred Otalgia
    • Globus sensation
    • Weight loss
  • Differentials
    • Fungal laryngitis
    • Sarcoidosis
    • Tuberculosis
    • Wegener’s granulomatosis
    • Benign vocal cord tumors
      • Polyps
      • Cysts
      • Hemangioma
      • Papilloma
  • Investigations
    • Indirect laryngoscopy
    • Flexible nasolaryngoscopy to visualize cord mobility
    • Rigid endoscopy of the larynx
    • Direct laryngoscopy under general anaesthesia and biopsy
    • Chest X-ray for chest metastasis, mediastinal nodes, and co-existing lung disease
    • CT scan of the base of the skull to the thoracic inlet
    • PET scan for follow-up and detection of distant metastases
    • Pulmonary function tests
    • Liver function tests
    • Urea and Creatinine
    • Electrolytes
    • Full Hemogram
  • Treatment of Carcinoma in Situ and Micro-Invasive Carcinoma
    • Smoking and alcohol Cessation
    • Radiation therapy or surgical excision
    • Radiation for recurrence after initial excision
    • Follow-up q2-3 months for 5 years
    • Excisional biopsy q3months until 2 consecutive negative results for microinvasive carcinoma
    • CO2 laser (does not provide biopsy specimen)
  • Treatment of Laryngeal Carcinoma
    • Primary radiation to the primary site
    • CO2 laser
    • Conservative Laryngeal Surgery
    • Total Laryngectomy and neck dissection
    • Organ Preservation
      • Induction chemotherapy, then Chemoradiation
      • Chemoradiation only
    • Palliation
  • Post-operative complications
    • Fistula
    • Tracheotomy Complications:
      • Pneumothorax
      • Haemorrhage
      • Subcutaneous emphysema
    • Speech alterations
    • Swallowing problems
    • Persistent aspiration
    • Bronchopneumonia
    • Esophageal or pharyngeal stenosis
    • Perichondritis and shondritis
    • Stomal stenosis
  • Post-operative voice management
    • Writing
    • Artificial larynx (electrolarynx)
    • Esophageal speech
    • Tracheoesophageal Puncture

AJCC T Staging comparison

StageSupraglotticGlotticSubglottic
T1Limited to 1 subsite, normal cordsLimited to the vocal foldsLimited to the subglottis
T2>1 subsite or adjacent spread, no fixationExtends the supra/subglottis or ↓ mobilityExtends to the vocal cords
T3Cord fixation or invasion (pre-epiglottic/paraglottic space, thyroid cartilage)Cord fixation or paraglottic invasionCord fixation or paraglottic invasion
T4Invades beyond the larynx / major structuresAdvanced invasionAdvanced invasion
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Leave a Reply

A moment of your time
Step 1 of 2

You are the reason this exists. Got 60 seconds? Help us improve Hyperexcision for every medical student who uses it.

The Hyperexcision Team